{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T14:20:30Z","timestamp":1794406830257,"version":"4.9.0"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Infliximab (IFX), a first-line treatment for moderate to severe Crohn\u2019s disease (CD), has immunomodulatory effects that increase the risk of opportunistic infections. Although IFX-associated invasive fungal infections have received widespread attention, IFX-associated superficial cutaneous fungal infections, such as Malassezia folliculitis (MF), have not been fully recognized. Herein, we present a case of a 19-year-old female patient with moderately active CD who rapidly developed facial erythema, inflammatory papules, and nodular lesions after treatment with IFX. Initially, she was diagnosed with acne vulgaris, but topical and oral antibiotic treatments were ineffective. After completing five IFX infusions, she not only had no relief of gastrointestinal symptoms, but also had progressive exacerbation of the cutaneous lesions. Fungal microscopy revealed abundant Malassezia spores, confirming the diagnosis of MF. Subsequently, IFX was discontinued, and treatment was switched to Ustekinumab (UST). Following this therapeutic adjustment, the patient demonstrated simultaneous resolution of both gastrointestinal and cutaneous symptoms. Notably, the facial lesions completely resolved after three UST infusions without the use of antifungal drugs. This case is the first report of MF induced by IFX therapy in a CD patient. It highlights that acneiform eruptions emerging during biologic therapy may represent cutaneous fungal manifestations. Early recognition and timely adjustment of treatment regimens are essential to prevent potential systemic fungal infections.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1611893","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T05:31:30Z","timestamp":1754976690000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Facial Malassezia folliculitis following infliximab treatment in Crohn\u2019s disease"],"prefix":"10.3389","volume":"16","author":[{"given":"Liji","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoyu","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beiping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianwen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiying","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101050","article-title":"Integrative multi-omics deciphers the spatial characteristics of host-gut microbiota interactions in Crohn\u2019s disease","volume":"4","author":"Gao","year":"2023","journal-title":"Cell Rep Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","article-title":"British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults","volume":"68","author":"Lamb","year":"2019","journal-title":"Gut"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjae091","article-title":"ECCO guidelines on therapeutics in crohn\u2019s disease: medical treatment","volume":"18","author":"Gordon","year":"2024","journal-title":"J Crohns Colitis"},{"key":"B4","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1093\/ecco-jcc\/jjac133","article-title":"Opportunistic infections in patients with inflammatory bowel disease treated with advanced therapies: A systematic review and meta-analysis of randomized controlled trials","volume":"17","author":"Olivera","year":"2023","journal-title":"J Crohns Colitis"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/myc.12753","article-title":"Fungal infections in patients with inflammatory bowel disease: A systematic review","volume":"61","author":"Stamatiades","year":"2018","journal-title":"Mycoses"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae444","article-title":"Incidence and risk factors for invasive fungal infections in patients initiating tumor necrosis factor-alpha inhibitors for inflammatory bowel disease and rheumatoid arthritis","volume":"80","author":"Hennessee","year":"2025","journal-title":"Clin Infect Dis"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e73429","DOI":"10.7759\/cureus.73429","article-title":"Malassezia folliculitis: pathogenesis and diagnostic challenges","volume":"16","author":"Mart\u00ednez-Ortega","year":"2024","journal-title":"Cureus"},{"key":"B8","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1080\/09546630802155073","article-title":"Infliximab-induced acne: a new case and review of published reports","volume":"20","author":"Steels","year":"2009","journal-title":"J Dermatol Treat"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.12416","article-title":"Acneiform eruption as a probable paradoxical reaction to adalimumab","volume":"54","author":"Fern\u00e1ndez-Crehuet","year":"2015","journal-title":"Int J Dermatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1086\/430000","article-title":"Tumor necrosis factor inhibition and invasive fungal infections","author":"Filler","year":"2005","journal-title":"Clin Infect Dis"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185x.12659","article-title":"Serious infection during etanercept, infliximab and adalimumab therapy for rheumatoid arthritis: A literature review","volume":"19","author":"Downey","year":"2016","journal-title":"Int J Rheum Dis"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(11)60839-2","article-title":"Fungal infections complicating tumor necrosis factor alpha blockade therapy","volume":"83","author":"Tsiodras","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00510-16","article-title":"Disruption of early tumor necrosis factor alpha signaling prevents classical activation of dendritic cells in lung-associated lymph nodes and development of protective immunity against cryptococcal infection","volume":"7","author":"Xu","year":"2016","journal-title":"mBio"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmcr.2021.101459","article-title":"Isolated pulmonary cryptococcosis in a patient with Crohn\u2019s disease treated with infliximab: A case report and literature review","volume":"33","author":"Hussein","year":"2021","journal-title":"Respir Med Case Rep"},{"key":"B15","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.idc.2020.02.010","article-title":"Fungal infections potentiated by biologics","volume":"34","author":"Davis","year":"2020","journal-title":"Infect Dis Clin North Am"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1038\/s41598-017-01400-4","article-title":"Tumor necrosis factor prevents Candida albicans biofilm formation","volume":"7","author":"Rocha","year":"2017","journal-title":"Sci Rep"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e13534","DOI":"10.7759\/cureus.13534","article-title":"Malassezia (Pityrosporum) folliculitis masquerading as recalcitrant acne","volume":"13","author":"Malgotra","year":"2021","journal-title":"Cureus"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000003119","article-title":"Drug-induced acne in inflammatory bowel disease: A practical guide for the gastroenterologist","volume":"120","author":"Temido","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1999.02768.x","article-title":"The quality of life in acne: a comparison with general medical conditions using generic questionnaires","volume":"140","author":"Mallon","year":"1999","journal-title":"Br J Dermatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijwd.2017.10.004","article-title":"How acne bumps cause the blues: the influence of acne vulgaris on self-esteem","volume":"4","author":"Gallitano","year":"2018","journal-title":"Int J Women\u2019s Dermatol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.02.040","article-title":"Acne vulgaris and risk of depression and anxiety: A meta-analytic review","volume":"83","author":"Samuels","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13191","article-title":"Acne and quality of life - impact and management","author":"Gieler","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjac153","article-title":"Pneumocystis jirovecii pneumonia in patients with inflammatory bowel disease-a case series","volume":"17","author":"Vieujean","year":"2023","journal-title":"J Crohns Colitis"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-020-06181-x","article-title":"Histoplasmosis in inflammatory bowel disease with tumor necrosis factor-alpha inhibitors: safe to continue biologics","volume":"66","author":"Jansson-Knodell","year":"2021","journal-title":"Dig Dis Sci"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/apt.18110","article-title":"Network meta-analysis: Comparative onset of early effect of biologics and small molecules in moderately to severely active luminal Crohn\u2019s disease","volume":"60","author":"Attauabi","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2025.2486309","article-title":"Infection toxicity assessment of tumor necrosis factor \u03b1 inhibitors in the treatment of IBD: a real-world study based on the US food and drug administration adverse events reporting system (FAERS)","author":"Cheng","year":"2025","journal-title":"Expert Opin Drug Saf"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1177\/17562848241265013","article-title":"Comparative risk of serious infections and tuberculosis in Korean patients with inflammatory bowel disease treated with non-anti-TNF biologics or anti-TNF-\u03b1 agents: a nationwide population-based cohort study","volume":"17","author":"Kim","year":"2024","journal-title":"Ther Adv Gastroenterol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.3.6.17815","article-title":"Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders","volume":"3","author":"Benson","year":"2011","journal-title":"mAbs"},{"key":"B29","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2147\/jir.s157358","article-title":"Clinical utility of ustekinumab in Crohn\u2019s disease","volume":"11","author":"Kotze","year":"2018","journal-title":"J Inflammation Res"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1016\/j.cgh.2022.01.013","article-title":"Risk of infections with ustekinumab and tofacitinib compared to tumor necrosis factor \u03b1 Antagonists in inflammatory bowel diseases","volume":"20","author":"Cheng","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1016\/j.cgh.2022.10.029","article-title":"Comparative safety and effectiveness of biologic therapy for crohn\u2019s disease: A CA-IBD cohort study","volume":"21","author":"Singh","year":"2023","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1611893\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T05:31:33Z","timestamp":1754976693000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1611893\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":31,"alternative-id":["10.3389\/fimmu.2025.1611893"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1611893","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]},"article-number":"1611893"}}